NovaBridge Biosciences (NBP) — Financial Flexibility Index
NovaBridge Biosciences (NBP) has a Financial Flexibility Index of 0.10x as of September 2025. Free cash flow of $13.15 Million (operating CF $13.15 Million minus capex $41.00) represents 0% of total liabilities ($131.67 Million). Check total reinvestment intensity of NovaBridge Biosciences to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NovaBridge Biosciences Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for NovaBridge Biosciences across 8 annual periods. For the full cash flow conversion analysis, see NBP cash flow conversion.
Annual Financial Flexibility Index for NovaBridge Biosciences (2017–2024)
Year-by-year free cash flow to debt coverage for NovaBridge Biosciences. Explore NBP debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -4.57x | $-52.60 Million | $-52.65 Million | $11.52 Million | ▼ -5521.1% |
| 2023 | -0.08x | $-72.69 Million | $-72.85 Million | $894.81 Million | ▲ +91.8% |
| 2022 | -0.99x | $-1.06 Billion | $-1.10 Billion | $1.07 Billion | ▼ -9.6% |
| 2021 | -0.91x | $-943.16 Million | $-973.09 Million | $1.04 Billion | ▼ -244.9% |
| 2020 | 0.62x | $441.57 Million | $433.56 Million | $706.65 Million | ▲ +375.5% |
| 2019 | -0.23x | $-855.74 Million | $-867.98 Million | $3.77 Billion | ▼ -183.8% |
| 2018 | -0.08x | $-266.30 Million | $-280.70 Million | $3.33 Billion | ▲ +54.3% |
| 2017 | -0.17x | $-231.83 Million | $-252.16 Million | $1.33 Billion | — |